Am­gen comes in sec­ond with its lat­est batch of KRAS da­ta, but its ri­val is still hav­ing prob­lems catch­ing up

Am­gen once again finds it­self tout­ing KRAS G12C da­ta that don’t mea­sure up to a ri­val at Mi­rati, as the small­er play­er strug­gles to play catch-up.

Af­ter the mar­ket closed on Mon­day, the phar­ma gi­ant post­ed a set of new da­ta from their Lumakras (so­tora­sib) team, spot­light­ing a 21% ob­jec­tive re­sponse rate in the Code­BreaK 100 Phase I/II tri­al among 38 pa­tients with KRAS G12C-mu­tat­ed ad­vanced pan­cre­at­ic can­cer. And re­searchers tracked a me­di­an pro­gres­sion free sur­vival rate of 4 months with a me­di­an over­all sur­vival rate that neared 7 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER